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1. Preface and acknowledgements 
Dipeptidyl peptidase IV (DPP-IV) and Dipeptidyl peptidase-IV activity and/or structure 
homologues such as fibroblast activation protein (FAP) and their possible involvement 
in the pathogenesis of malignant tumors have sparked my interest during medical 
studies and I have continued working in the field since then. In this habilitation thesis I 
first provide a short introduction of these “moonlighting” molecules that are involved in 
various aspects of physiological and pathological processes. Subsequently, I summarize 
the results of our work published over the past few years which focused among others 
on DPP-IV and FAP in the context of two recalcitrant human malignancies. In the first 
section of the results, an overview of our studies in pancreatic ductal adenocarcinoma is 
provided. The second part sums up our research on DPP-IV and FAP in glioblastoma, 
the most common and the most deadly form of a primary brain tumor. Detailed 
information on the experimental approaches and results can be found in our published 
papers that are included in this habilitation thesis (see attachments). Attachments also 
contain our review articles and book chapters that give a more general overview of 
proteases in brain tumors, discuss approaches to early detection of sporadic pancreatic 
cancer and summarize the information regarding the role and therapeutic targeting of 
DPP-IV and FAP in cancer.  
The results presented in this work could not have been obtained without the contribution 
of many people with whom I had the opportunity and the privilege to collaborate. I 
would especially like to thank the members of the Laboratory of Cancer Cell Biology at 
the First Faculty of Medicine of the Charles University, who provided help during 
experimental work and were a constant source of support and inspiration. My big thanks 
go to Aleksi Sedo, who introduced me to the field of “Dipeptidyl peptidase IV activity 
and/or structure homologues”, was a mentor during my studies and provided support 
throughout the work. I would also like to thank Evzen Krepela for always being a 
source of expertise and critical comments and Premysl Fric, who introduced me to the 
field of pancreatic cancer.  
Finally, I would like to thank my wife Vendula for patience and understanding and my 
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3. List of abbreviations 
ADA = Adenosine deaminase 
Akt = Protein Kinase B 
BNP = Brain natriuretic peptide 
CARMA1 = Caspase recruitment domain-containing protein 11 
CCL = Chemokines belonging to the CC family 
CD = Cluster of differentiation 
CXCL = Chemokines belonging to the CXC family 
DASH = Dipeptidyl peptidase-IV activity and/or structure homologues 
DM = Diabetes mellitus 
DPP = Dipeptidyl peptidase 
EC = Enzyme Commission 
ELISA = Enzyme-Linked ImmunoSorbent Assay 
EGFR = Epidermal Growth Factor Receptor 
FAP = Fibroblast activation protein, seprase 
FGF21 = Fibroblast growth factor 21 
G-CSF = Granulocyte colony-stimulating factor 
GFAP = Glial fibrillary acidic protein 
GHRH = Growth hormone releasing hormone 
GIP = Gastric inhibitory polypeptide/ glucose-dependent insulinotropic peptide 
GLP = Glucagon-like peptide 
GM-CSF = Granulocyte-macrophage colony-stimulating factor 
GRP = Gastrin-releasing peptide 
GSC= Glioma stem-like cells 
HCV = Hepatitis C virus 
HIV = Human immunodeficiency virus  
IL = Interleukin 
MERS = Middle East respiratory syndrome 
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NHE3 = Sodium–hydrogen exchanger 3 
NPY = Neuropeptide Y 
PACAP = Pituitary adenylate cyclase-activating peptide 
PAR = Protease activated receptor 
PDAC = Pancreatic ductal adenocarcinoma 
PHM = Peptide Histidine-Methionine 
PYY = Peptide YY 
qRT-PCR = Real-Time Quantitative Reverse Transcription PCR 
SOX-2 = Transcription Factor SOX-2 
SP = Substance P 
SPRY2 = Sprouty (Drosophila) homolog 2 
TAT = Trans-activator of transcription 
TCGA = The Cancer Genome Atlas 
uPAR = Urokinase-type plasminogen activator (UPA) receptor 




4. Introduction  
Dipeptidyl peptidase-IV (DPP-IV, DPP4, CD26, adenosine deaminase complexing 
protein 2, EC 3.4.14.5) and fibroblast activation protein (FAP, Surface Expressed 
Protease [seprase], antiplasmin-cleaving enzyme [APCE], EC 3.4.2.1.B28), are non-
classical serine proteases belonging to S9B family and to “Dipeptidyl peptidase IV 
activity and/or structure homologues” (DASH) (Sedo and Malik 2001, Busek, Malik et 
al. 2004). The genes encoding these proteases are highly evolutionary conserved, are 
localized in close proximity on the long arm of chromosome 2 in humans and have 
similar organization, suggesting that they may be a product of gene duplication. The 
proteins encoded by these genes share several common characteristics, but exhibit 
substantial differences in tissue distribution and possible pathophysiological functions. 
DPP-IV and FAP proteins consist of 766 and 760 amino acid residues respectively, and 
exhibit 52% identity (Darmoul, Lacasa et al. 1992, Goldstein, Ghersi et al. 1997). Both 
DPP-IV and FAP are type II transmembrane proteins that contain a short cytoplasmic 
tail, a transmembrane region and a large glycosylated extracellular domain with the 













 in FAP (Goldstein, Ghersi et al. 1997, Lambeir, Durinx et al. 2003). DPP-IV is 
broadly expressed, although in a cell differentiation/activation-dependent manner, in 
lungs, liver, proximal convoluted tubules in the kidney, epithelial cells of the intestine, 
pancreas and prostate, placenta, and in certain types of endothelial and immune cells 
(for a review see (Lambeir, Durinx et al. 2003, Klemann, Wagner et al. 2016)). In 
contrast, FAP is only scarcely present under physiological conditions in adults, but is 
upregulated in states of tissue remodeling such as during embryonic development, in 
healing wounds, chronic inflammation and cancer (for a review see Attachment 1, 
(Jacob, Chang et al. 2012, Kelly, Huang et al. 2012)). Interestingly, a soluble form of 
both proteins lacking the intracellular part and the transmembrane region is present in 
body fluids (Durinx, Lambeir et al. 2000, Lee, Jackson et al. 2006). Co-expression and 
possible co-regulation of both proteases was reported by us and others in some types of 
cancer cells, migrating endothelial cells and fibroblasts (Wesley, Albino et al. 1999, 
Ghersi, Dong et al. 2002, Wesley, Tiwari et al. 2004, Ghersi, Zhao et al. 2006, 
Goscinski, Suo et al. 2008, Balaziova, Busek et al. 2011). Although the implications of 
these observations are currently largely speculative, it should be noted that both 
proteases share an overlapping set of substrates and likely act in concert during the 
remodeling of extracellular matrix. 
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DPP-IV and FAP are enzymatically active as dimers and cleave peptides and proteins 
that contain proline or alanine in the penultimate position at the N-terminus. In addition 
to this dipeptidyl aminopeptidase enzymatic activity, FAP also exhibits a post-proline 
endopeptidase activity (Aertgeerts, Levin et al. 2005, Edosada, Quan et al. 2006). Due 
to the unique structure of proline, most proteases do not cleave the peptide bonds 
adjacent to it and proline thus often prevents protein degradation or cleavage (Vanhoof, 
Goossens et al. 1995). Several chemokines, neuropeptides and incretins have been 
shown to be cleaved by DPP-IV and/or FAP with their resulting inactivation, activation 
or change in receptor preference (Figure 1, for a review see Attachment 2, (Mentlein 
1999, Busek, Malik et al. 2004, Klemann, Wagner et al. 2016)). 
 
Figure 1. Substrate specificity and biologically active peptides cleaved by DPP-IV 
and/or FAP. 
BNP = Brain natriuretic peptide, CCL/CXCL = Chemokines belonging to the CC and 
CXC family respectively, FGF21 = Fibroblast growth factor 21, G-CSF = Granulocyte 
colony-stimulating factor, GHRH = Growth hormone releasing hormone, GIP = 
Gastric inhibitory polypeptide/ glucose-dependent insulinotropic peptide, GLP-1, 2 = 
Glucagon-like peptide-1, 2, GM-CSF = Granulocyte-macrophage colony-stimulating 
factor, GRP = Gastrin-releasing peptide, IL-3 = Interleukin 3, PACAP = Pituitary 
adenylate cyclase-activating peptide, PHM = Peptide Histidine-Methionine, SP = 
Substance P, PYY = Peptide YY, NPY = Neuropeptide Y, SPRY2 = Sprouty 





In addition to proteolytically modifying several biopeptides, both proteases are known 
to bind other proteins outside of their catalytic site. The proteins interacting with DPP-
IV include human adenosine deaminase 1 (ADA), the protein phosphatase CD45, 
mannose 6-phosphate/insulin-like growth factor II receptor, caveolin-1, CARMA1, the 
chemokine receptor CXCR4, the HIV TAT and gp-120 proteins, the extracellular matrix 





exchanger isoform NHE3 (see (Klemann, Wagner et al. 2016) and references therein). 
In the case of FAP, formation of complexes with DPP-IV, caveolin-1, erlin-2, stomatin 
(Knopf, Tholen et al. 2015) and with Urokinase-type plasminogen activator receptor 
(uPAR) and alpha3 beta1 integrin (Artym, Kindzelskii et al. 2002) was reported in 
cancer associated fibroblasts and melanoma invadopodia, respectively.  
The “moonlighting” characteristics of both proteases, mediated by the cleavage of a 
wide variety of biologically active peptides and by “non-proteolytic” interactions with 
various molecules, lead to their involvement in various physiological and pathological 
states and processes (Figure 2).  
 
Figure 2. Physiological and pathological conditions and processes associated with 
deregulated expression or functional involvement of DPP-IV and/or FAP. 





Perhaps the best explored is the ability of DPP-IV to cleave and thereby inactivate 
several insulinotropic peptides (e.g. GLP-1, GIP, PACAP, NPY). Research in this area 
has led to the discovery that the use of DPP-IV resistant GLP-1 analogs or low-
molecular weight DPP-IV inhibitors (gliptins) improves insulin secretion and glucose 
homeostasis. Although our understanding of the exact underlying mechanisms is still 
incomplete (Omar and Ahren 2014, Mulvihill, Varin et al. 2017, Yabe, Seino et al. 
2018), both approaches are currently routinely used in treating patients with type 2 
diabetes mellitus (DM) (Deacon, Mannucci et al. 2012). Together with its effect on 
insulinotropic peptides, DPP-IV appears to have a negative influence on other 
mechanisms of glucose homeostasis regulation, particularly in obesity and metabolic 
syndrome. In an enzyme activity dependent manner, soluble DPP-IV impairs insulin 
sensitivity on the level of Akt (Protein Kinase B) phosphorylation in adipocytes and 
muscle cells (Lamers, Famulla et al. 2011). Recently, it has also been shown that 
soluble DPP-IV in combination with protease activated receptor 2 (PAR2)  activation 
by plasma factor Xa promotes inflammation in the visceral adipose tissue probably by 
binding caveolin-1 in macrophages (Ghorpade, Ozcan et al. 2018). Inhibition of DPP-
IV enzymatic activity has been shown to affect a broad spectrum of other processes in 
addition to glucoregulation. In preclinical studies, DPP-IV inhibitors seem to prevent 
the progression of atherosclerosis, which was recently confirmed in a clinical trial 
(Fadini and Avogaro 2013, Mita, Katakami et al. 2016, Duan, Rao et al. 2017). DPP-IV 
also participates on the pathogenesis of liver diseases and its inhibition alleviates 
hepatic steatosis and cirrhosis (Itou, Kawaguchi et al. 2013, Baumeier, Schluter et al. 
2017, Nakamura, Fukunishi et al. 2017, Amano, Tsuchiya et al. 2018). Most likely by 
modulating the activity of various biopeptides, DPP-IV seems to participate in the 
regulation of food intake and energy expenditure and in a preclinical study its inhibition 
was shown to have anti-obesity effects (Lee, Kim et al. 2014). Nociception, especially 
in the setting of inflammatory and neuropathic pain, seems to be influenced by DPP-IV. 
DPP-IV inhibition has analgesic and anti-inflammatory effects in several models 
(Ujhelyi, Ujhelyi et al. 2014, Kiraly, Kozsurek et al. 2018). In animal studies, DPP-IV 
inhibition was shown to have beneficial effects in neurological disorders such as 
Parkinson’s and Alzheimer’s disease and multiple sclerosis, possibly by promoting the 
neurotrophic effects of various DPP-IV substrates and by immunoregulatory 
mechanisms (see (Al-Badri, Leggio et al. 2018) for a review). Case reports have been 
published describing improvement of psoriasis in patients using sitagliptin (van Lingen, 
Poll et al. 2008, Nishioka, Shinohara et al. 2012, Lynch, Tobin et al. 2014). By 
12 
 
increasing the bioavailability of GLP-1, CXCL12 (stromal cell derived factor 1) and 
other biopeptides, DPP-IV inhibition may have beneficial effects in renal and 
cardiovascular diseases including myocardial infarction (for a review see (Hocher, 
Reichetzeder et al. 2012)). Recently, soluble DPP-IV has been demonstrated to mediate 
endothelial dysfunction by activating protease activated receptors (PAR) in endothelial 
cells and its inhibition may thus preserve endothelial function in cardiometabolic 
diseases (Romacho, Vallejo et al. 2016). By modulating the bioactivity of GM-CSF 
(granulocyte-macrophage colony-stimulating factor), G-CSF (granulocyte colony-
stimulating factor), erythropoietin and CXCL12, DPP-IV seems to play an important 
role in the regulation of hematopoiesis.  Inhibition of DPP-IV is therefore being tested 
as an approach to improve hematopoietic recovery after irradiation, chemotherapy, or 
hematopoietic stem cell transplantation (Broxmeyer, Hoggatt et al. 2012). DPP-IV is 
well known to be involved in T cell activation and function (Ohnuma, Hosono et al. 
2011, Klemann, Wagner et al. 2016), and changes in DPP-IV expression and/or activity 
have been reported by us and others in various autoimmune diseases including 
rheumatoid arthritis (Ellingsen, Hornung et al. 2007, Sromova, Busek et al. 2015), 
inflammatory bowel diseases (Hildebrandt, Rose et al. 2001), multiple sclerosis (Tejera-
Alhambra, Casrouge et al. 2014) or graft versus host disease (Ohnuma, Hatano et al. 
2015). 
DPP-IV is also implicated in the pathogenesis of viral diseases. DPP-IV mediated 
cleavage of CXCL10 contributes to viral persistence in hepatitis C infection (Riva, 
Laird et al. 2014). In HIV infection, DPP-IV is thought to influence the entry of the 
virus into target cells possibly by serving as a co-receptor and cleaving chemokines that 
prevent HIV interaction with its other co-receptors (see (Lambeir, Durinx et al. 2003) 
for a review). Recently, DPP-IV has been identified as a receptor for the Middle East 
respiratory syndrome (MERS) coronavirus (Lu, Hu et al. 2013, Raj, Mou et al. 2013) 
and antibodies blocking the interaction between spike protein S1 and DPP-IV are being 
developed as possible new treatments of this disease (Ohnuma, Haagmans et al. 2013).  
Targeting DPP-IV thus seems an attractive approach in various pathologies. 
Nevertheless, the multitude of functions of DPP-IV itself and of its substrates raises 
some concerns regarding the safety of gliptins (Matteucci and Giampietro 2009, Stulc 
and Sedo 2010). For example, we and others have recently reported that sitagliptin 
treatment may cause changes of the proportion of lymphocyte subpopulations in 
patients with type 2 DM (Aso, Fukushima et al. 2015, Sromova, Busek et al. 2016). 
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Although the rate of side effects of gliptins is generally considered to be comparable to 
placebo, several reports have described cases with gliptin-associated arthritis (Yokota 
and Igaki 2012, Saito, Ohnuma et al. 2013, Crickx, Marroun et al. 2014) and skin 
diseases (Skandalis, Spirova et al. 2012, Attaway, Mersfelder et al. 2014, Bene, 
Jacobsoone et al. 2015, Keseroglu, Tas-Aygar et al. 2017). Furthermore, the question of 
possible role of gliptins in the development of malignancies remains currently 
unresolved (Raz, Bhatt et al. 2014, Tseng 2016, Overbeek, Bakker et al. 2018).  
The functions of FAP under physiological conditions are largely unknown. In mice, its 
absence during embryonic development does not lead to developmental defects, mice 
are fertile and have no significant differences in any of the major organs or biochemistry 
parameters (Niedermeyer, Kriz et al. 2000, Niedermeyer, Garin-Chesa et al. 2001). 
Recent reports demonstrating that FAP cleaves fibroblast growth factor 21 (FGF21), a 
protein controlling energy metabolism and insulin sensitivity (Dunshee, Bainbridge et 
al. 2016, Zhen, Jin et al. 2016), nevertheless point to its possible involvement in the 
regulation of metabolism. Indeed, FAP knockout mice are protected against diet-
induced obesity and pharmacological inhibition of FAP enhances levels of FGF21 and 
has several metabolic benefits in obese mice (Sanchez-Garrido, Habegger et al. 2016). 
The soluble form of FAP further cleaves and thereby converts alpha-2-antiplasmin into 
a more potent inhibitor of plasmin (Lee, Jackson et al. 2004). FAP may thus participate 
on the pathogenesis of thromboembolic diseases and its inhibition could enhance the 
thrombolytic activity of plasmin (Lee, Jackson et al. 2011, Uitte de Willige, Malfliet et 
al. 2013, Uitte de Willige, Malfliet et al. 2015). FAP is strongly upregulated in disease 
states associated with tissue remodeling such as liver cirrhosis, pulmonary fibrosis, 
arthritis, remodeling heart tissue after myocardial infarction, advanced atherosclerotic 
lesions, strictured regions in Crohn’s disease and a variety of cancers. In these 
conditions, FAP seems to contribute to the remodeling of extracellular matrix, induction 
of immunosuppression and promotion of the malignant phenotype of cancer cells 
(reviewed in Attachment 1). 
DPP-IV and FAP are deregulated in several types of cancers, participate on their 
pathogenesis and represent possible biomarkers and therapeutic targets. This topic has 
been reviewed by us (Attachment 1, 2) and others (Yu, Yao et al. 2010, Beckenkamp, 
Davies et al. 2016), and therefore only selected examples are mentioned here. DPP-IV 
participates on the pathogenesis of melanoma and malignant mesothelioma. Normal 
melanocytes express DPP-IV (Houghton, Albino et al. 1988). DPP-IV is downregulated 
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by promoter methylation in melanoma cell (McGuinness and Wesley 2008) and its re-
expression induces profound phenotypic changes including loss of tumorigenicity, 
anchorage-independent growth and a reversal in a block in differentiation and an 
acquired dependency on exogenous growth factors, in part through its enzymatic 
activity (Wesley, Albino et al. 1999). In contrast to this tumor suppressor role in 
melanoma, DPP-IV seems to be important for the malignant phenotype of 
mesothelioma cells. DPP-IV mediates adhesion of the cells to extracellular matrix, 
enhances their invasion and is expressed in a subset of mesothelioma stem-like cells 
(Inamoto, Yamada et al. 2007, Ghani, Yamazaki et al. 2011, Okamoto, Iwata et al. 
2014). FAP is in general believed to promote the malignant phenotype of cancer cells 
(well documented e.g. in oral squamous cell carcinoma (Wang, Wu et al. 2014)). 
Nevertheless, it was reported that it acts as a tumor suppressor in melanoma (Wesley, 
Albino et al. 1999, Ramirez-Montagut, Blachere et al. 2004). Regarding the role of 
DPP-IV and FAP as biomarkers, absence of DPP-IV was proposed to discriminate 
malignant melanomas from deep penetrating nevi (Roesch, Wittschier et al. 2006), 
while its presence may be useful in predicting the malignant character of thyroid lesions 
(Tanaka, Umeki et al. 1995, Hirai, Kotani et al. 1999, Aratake, Umeki et al. 2002, de 
Micco, Savchenko et al. 2008, Zheng, Liu et al. 2015). Expression of FAP in several 
tumor types is associated with more aggressive disease (reviewed in Attachment 1). 
Interestingly, lower plasma level of FAP in combination with other serum markers was 
proposed to be useful for the early detection of colorectal cancer (Wild, Andres et al. 
2010, Werner, Krause et al. 2016).  
The role of FAP as a possible therapeutic target in cancer has been documented by a 
number of preclinical and phase I clinical studies using low molecular weight inhibitors, 
FAP activated prodrugs, anti-FAP antibodies and their conjugates, FAP-chimeric 
antigen receptor (CAR) T cells, and FAP vaccines (reviewed in Attachment 1). 
Targeting of DPP-IV by humanized monoclonal antibodies is being tested as a novel 
treatment for malignant mesothelioma (Inamoto, Yamada et al. 2007, Raphael, Le Teuff 
et al. 2014) and a recent phase I trial suggests that it is well tolerated and may stabilize 
disease in patients with advanced/refractory mesothelioma (Angevin, Isambert et al. 
2017). Preclinical studies suggest that low molecular weight DPP-IV inhibitors may 
inhibit metastatic spread of cancer cells in colorectal carcinoma (Jang, Baerts et al. 
2015). In addition, DPP-IV inhibition can enhance antitumor immune response by 
preserving biologically active CXCL10, thereby increasing the infiltration of 
lymphocytes expressing the CXCR3 receptor into the tumor. That study also 
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demonstrated that inhibition of DPP-IV may have a synergistic effect with currently 
used immunotherapeutic approaches (Barreira da Silva, Laird et al. 2015). 
The few abovementioned examples clearly illustrate that both proteases can act – by 
various mechanisms and in a tumor type-dependent manner – as either tumor promoters, 
or tumor suppressors. Therefore detailed analysis of their possible role and potential 
diagnostic or therapeutic applicability in particular tumor types is necessary. Below I 
summarize our studies that evaluated the possible pathophysiological role of DPP-IV 
and FAP and their potential use as biomarkers and therapeutic targets in pancreatic 




5. Summary of published papers 
5.1 DPP-IV and FAP in pancreatic cancer 
Pancreatic ductal adenocarcinoma (PDAC) is the main histological tumor type 
originating in the pancreas. PDAC mostly occurs as sporadic; similarly to other tumor 
types only 5 to 10% cases are estimated to have an inherited component (Ryan, Hong et 
al. 2014). The incidence of PDAC in the Czech Republic is one of the highest in the 
world, increases steadily and currently reaches 20 cases per 100 000 
(http://www.svod.cz/). A complete surgical removal of the tumor is the only potentially 
curative therapy. Most patients are however diagnosed with an advanced stage disease 
and less than 20% are candidates for surgery. The prognosis of PDAC is thus grim – the 
5-year survival rate is less than 6% and most of the patients die within one year from 
diagnosis. Due to its increasing incidence and dismal prognosis, PDAC is estimated to 
become the second leading cause of cancer-related deaths in the United States by 2020 
(Chari, Kelly et al. 2015). Absence of effective screening tools is an important 
contributor to the late diagnosis of these tumors. Approaches to identify persons with 
potentially curable premalignant states and early stage PDAC are needed as reviewed by 
us (Attachment 9) and others (Hanada, Okazaki et al. 2015, Chari, Kelly et al. 2015). 
Diabetes is present in more than 50% of PDAC patients (Chari, Leibson et al. 2005) and 
newly diagnosed impairment of glucose homeostasis, in particular when accompanied 
by weight loss, is an early sign of PDAC. The differentiation from the initial stage of 
the much more prevalent “common” type 2 DM is currently not possible and the 
pathogenetic mechanisms underlying the increased insulin resistance and beta cell 
dysfunction in PDAC are incompletely understood (Attachment 10, (Cui and Andersen 
2012, Sah, Nagpal et al. 2013)). 
Both the circulating and cell membrane bound DPP-IV has been shown to be involved 
in various aspects of glucoregulation, in general reducing insulin secretion from beta 
cells and increasing insulin resistance in target tissues (Lamers, Famulla et al. 2011, 
Deacon, Mannucci et al. 2012, Omar and Ahren 2014, Mulvihill, Varin et al. 2017, 
Ghorpade, Ozcan et al. 2018, Yabe, Seino et al. 2018). Similarly, FAP seems to be 
involved in the regulation of energy metabolism through FGF21 cleavage (Sanchez-
Garrido, Habegger et al. 2016). 
In a collaborative project we therefore analyzed the role of DPP-IV and FAP in PDAC 
with a special focus on their possible association with an impaired glucose homeostasis. 
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Attachment 3 contains our published findings revealing the co-expression of the two 
proteases in Langerhans islets. By catalytic histochemistry and by using a highly 
selective DPP-IV inhibitor sitagliptin, we detected the enzymatic activity of DPP-IV in 
ducts of exocrine pancreas, which was in accord with previously published data. 
Somewhat surprisingly, we also observed strong DPP-IV positivity in the Langerhans 
islets in PDAC patients. We confirmed that this reflects the physiological expression of 
DPP-IV in an adult human pancreas using morphologically normal tissue samples from 
nondiabetic patients with a benign serous cystadenoma. Using immunohistochemistry, 
we proved that DPP-IV is expressed in pancreatic alpha cells and is co-expressed with 
FAP in more than 90% of the alpha cells. 
Changes in plasma and tissue levels of DPP-IV and FAP in PDAC and their possible 
association with impaired glucoregulation in PDAC were the focus of the next paper 
(Attachment 4). Impaired glucoregulation was present in 79% of the patients in our 
study and was diagnosed within 2 years before the diagnosis of PDAC in the majority of 
them. Using paired samples of tumorous and non-tumorous tissue from PDAC patients, 
we demonstrated that DPP-IV-like enzymatic activity was increased in the tumorous 
tissue due to an increase of both canonical DPP-IV (CD26) and other DPP-IV-like 
enzymatic activity exhibiting molecules. Concordantly with previous reports, we 
observed increased FAP expression in PDAC tissues, nevertheless abundant FAP 
expression was also observed in several non-tumorous samples from PDAC patients, 
particularly when the morphological features of chronic pancreatitis were present. Using 
immunohistochemistry we showed that DPP-IV and FAP expression was localized in 
cancer cells and also in stromal cells. There was a trend for more pronounced 
expression in stromal cells in the proximity of cancer cells, suggesting that paracrine 
signaling from cancer cells is responsible for DPP-IV and FAP upregulation in the 
stroma (see Attachment 1 for a review of FAP expression regulation). In part of the 
samples, Langerhans islets surrounded by DPP-IV and FAP expressing cancer 
associated stroma were observed. We further evaluated whether the levels of circulating 
DPP-IV and FAP are changed in PDAC patients with a special focus on the possible 
association of these changes with the early symptoms of PDAC, i.e. new onset diabetes 
(duration less than 2 years) and weight loss greater than 2kg. DPP-IV enzymatic activity 
was highest in PDAC patients exhibiting both of these early symptoms and the 
difference was statistically significant compared to patients with type 2 diabetes without 
PDAC. A similar trend was observed for healthy controls, but the difference did not 
reach statistical significance. Contrary to this, detection of DPP-IV (CD26) by ELISA 
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revealed highest levels in patients with type 2 diabetes without PDAC. Consequently, 
the ration between DPP-IV enzymatic activity and DPP-IV protein concentration 
(specific enzymatic activity of DPP-IV) was significantly higher in PDAC compared to 
patients with type 2 diabetes without PDAC. Plasma FAP levels were lower in PDAC, 
which was consistent with previous studies in PDAC and other cancers (Wild, Andres et 
al. 2010, Javidroozi, Zucker et al. 2012), and rose after tumor removal suggesting a 
close association between the presence of the tumor and plasma FAP levels.  
We evaluated the possible utility of plasma DPP-IV and FAP as biomarkers of PDAC 
associated impairment of glucoregulation using semiparametric logistic regression 
based on a generalized additive model. Of the analyzed variables, a specific DPP-IV 
(CD26) enzymatic activity (i.e. the ratio between measured DPP-IV enzymatic activity 
and CD26 antigen concentration) was the best predictor for discriminating PDAC 
patients with recently diagnosed diabetes/prediabetes from type 2 DM without PDAC 
and improved the predictive ability of CA19-9.  
The abovementioned studies contribute to our understanding of the potential role of 
DPP-IV and FAP in the pathogenesis of PDAC. In addition, they suggest that both 
proteases may have an important role in regulating the signaling of biopeptides directly 
within human Langerhans islets under physiological conditions. There are substantial 
differences in the cytoarchitecture of Langerhans islets (e.g. (Bosco, Armanet et al. 
2010)) as well as in DPP-IV expression in individual animal species (Schrader and West 
1985, Dinjens, ten Kate et al. 1989, Dorrell, Grompe et al. 2011). Previous reports 
suggested that DPP-IV is present in the secretory granules of alpha cells in pigs 
(Poulsen, Hansen et al. 1993), but a study in human autoptic material (Dinjens, ten Kate 
et al. 1989) detected DPP-IV immunoreactivity in the epithelial cells of intra- and 
interlobular pancreatic ducts, but not in the Langerhans islets. Our data regarding DPP-
IV expression in human pancreatic alpha cells were independently confirmed by 
concurrently published studies in autoptic material and isolated pancreatic islets (Liu, 
Omar et al. 2014, Omar, Liehua et al. 2014, Augstein, Naselli et al. 2015). Omar et al. 
has shown that isolated human islets exposed to a DPP-IV inhibitor exhibited increased 
secretion of intact GLP-1 and insulin (Omar, Liehua et al. 2014), further supporting the 
role of DPP-IV in the local regulation of insulin secretion. Interestingly, intrapancreatic 
GLP-1 production may be increased in type 2 DM (Marchetti, Lupi et al. 2012) and the 
intrapancreatic effects of DPP-IV inhibitors may thus play an important role in their 
glucose lowering action. The possible physiological role of FAP in human pancreas 
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remains to be determined. GLP-1 and GIP, the main incretins, are rather inefficient FAP 
substrates (Keane, Nadvi et al. 2011). On the other hand, the pleiotropic metabolic 
regulator FGF21 has recently been demonstrated to be efficiently cleaved by FAP 
(Coppage, Heard et al. 2016, Dunshee, Bainbridge et al. 2016, Zhen, Jin et al. 2016). 
FGF21 seems to play an important role in regulating pancreatic endocrine cells under 
physiological and pathological states (Wente, Efanov et al. 2006, So, Cheng et al. 2015, 
Singhal, Fisher et al. 2016) and has pleiotropic metabolic effects in other organs 
(Degirolamo, Sabba et al. 2016). It remains to be established, to what extend this is 
affected by FAP mediated FGF21 cleavage. Mouse and rat FGF21 is resistant to FAP 
due to an amino acid substitution at the cleavage site (Dunshee, Bainbridge et al. 2016), 
disease models using these animal species will thus have to be used cautiously. 
In PDAC, tissue levels of DPP-IV and FAP are increased. Possible consequences of 
their upregulation remain largely speculative. The proteases may participate on the 
fibrotic reaction characteristic for PDAC. FAP positive cells are an important source of 
extracellular matrix. In addition, FAP together with other proteases produced by these 
cells contributes to the remodeling of the matrix and a creation of an environment 
facilitating tumor cell dissemination. FAP positive cells are further known to promote 
immunosuppression (see Attachment 1), an important contributor to PDAC 
progression (Sideras, Braat et al. 2014).  
The high prevalence of impaired glucoregulation in our cohort of PDAC patients 
(Attachment 4) is consistent with the findings in other studies (see (Andersen, Korc et 
al. 2017) for a review). The pathogenetic mechanisms leading to the development of 
diabetes in PDAC are only poorly understood (Sah, Nagpal et al. 2013). Production of 
S-100A8 N-terminal peptide (Basso, Greco et al. 2006), adrenomedullin (Aggarwal, 
Ramachandran et al. 2012, Javeed, Sagar et al. 2015) and vanin-1 (Kang, Qin et al. 
2016) may lead to beta cell dysfunction and increased insulin resistance. Our results 
raise an interesting possibility that DPP-IV and possibly FAP may be contributing 
factors to the development of impairment of glucoregulation in PDAC. In our cohort we 
observed changes in the plasma concentrations of neuroendocrine mediators, several of 
which are potential or proven DPP-IV substrates (Attachment 11). Mean fasting 
plasmatic levels of GIP and PP were decreased in PDAC compared to patients with type 
2 diabetes without PDAC, and GIP concentrations rose after surgical removal of the 
tumor. Interestingly, GIP is known to be efficiently cleaved by DPP-IV. Concentrations 
of other DPP-IV and/or FAP substrates (GLP-1, NPY, PYY) were however not 
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changed. A limitation of our approach was that the assays could not differentiate 
between the cleaved and intact forms of the peptides. It therefore remains unclear, 
whether and to what extent the proteolytic cleavage may contribute to the observed 
decrease of GIP and PP in PDAC. Perhaps even more importantly, changes in systemic 
circulation may only poorly reflect the impact of the proteases on pancreatic beta cells. 
In this respect, the frequently observed close proximity of the Langerhans islets to FAP 
and/or DPP-IV expressing stromal cells may have a more important effect on the 
endo/para/autocrine loops regulating beta cell functions. For example, the impact of 
substantially increased tissue levels of FAP in PDAC on FGF21 signaling remains to be 
determined. In addition to increased enzymatic activity in the PDAC tissues, the 
systemic levels of DPP-IV enzymatic activity were increased in PDAC with impaired 
glucoregulation. This may not only lead to increased systemic degradation of 
biopeptides regulating insulin secretion, but soluble DPP-IV has also been shown to 
attenuate insulin signaling in adipocytes and skeletal muscle cells (Lamers, Famulla et 
al. 2011) and trigger inflammation in the visceral adipose tissue (Ghorpade, Ozcan et al. 
2018). 
In conclusion, our results suggest that DPP-IV and FAP may be implicated in the 
regulation of endocrine pancreas under physiological conditions. The increased 
expression of both proteases observed in patients with PDAC suggests that they may be 
involved in the pathogenesis of PDAC and may possibly contribute to the frequent co-
occurrence of PDAC and newly diagnosed diabetes mellitus. 
 
Summary of the main results of our work in PDAC:  
 DPP-IV and FAP are co-expressed in human alpha cells in Langerhans islets 
under physiological conditions. 
 Expression of DPP-IV and FAP is increased in PDAC tissues compared to 
matched paired non-tumorous pancreatic tissue. 
 DPP-IV and FAP are expressed by cancer and stromal cells in PDAC, including 
stromal cells in close proximity to Langerhans islets. 
 Plasma levels of DPP-IV enzymatic activity are increased in PDAC with recent 
onset DM and weight loss compared to patients with type 2 diabetes without 
PDAC. Plasma concentrations of GIP and PP are decreased in these patients. 
 DPP-IV and FAP may be contributing factors to the pathogenesis of PDAC- 
associated impairment of glucose homeostasis.  
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5.2 DPP-IV and FAP in glioblastoma 
Gliomas are the most common primary intraaxial brain tumors. According to the 
recently updated WHO classification (Louis, Perry et al. 2016), several entities are 
distinguished based on the histopathological and molecular characteristics of this 
heterogeneous group of tumors. Glioblastoma multiforme (GBM, WHO grade IV 
glioma) is the most common type of astrocytic tumors affecting mostly adults between 
the ages of 45 and 70 years. Although GBMs are relatively rare in terms of annual 
incidence (two to three per 100,000 adults per year), they represent an important cause 
of mortality and morbidity. The tumors are incurable- most patients die within one to 
two years from diagnosis (median survival of 15 months) and less than 5% patients 
survive 5 years despite multimodality treatment including maximal-safe surgical 
resection, adjuvant radiation therapy with concurrent and adjuvant temozolomide 
treatment (Weller, van den Bent et al. 2017).  
Localization of the tumors in a vital organ with a limited reparatory capacity is an 
important factor contributing to the dismal prognosis of this disease. In addition to that, 
several biological characteristics of the tumors play an important role. Extensive 
infiltration into the surrounding tissue precludes curative removal of the tumors and the 
dispersed glioma cells are highly resistant to conventional therapies. Glioblastomas are 
highly heterogeneous tumors with various molecular subtypes defined by specific 
molecular aberrations and transcriptional profiles being present in individual patients 
(Karsy, Gelbman et al. 2012, Aldape, Zadeh et al. 2015), and even within individual 
tumors (Sottoriva, Spiteri et al. 2013). Undifferentiated, self-renewing and highly 
tumorigenic glioblastoma stem-like cells (GSC) are thought to importantly contribute to 
several of these characteristics including tumor recurrence and therapeutic resistance 
(Lathia, Mack et al. 2015, Nakano 2015).  
In addition to cell-autonomous mechanisms operating in malignant cells, clues from 
their surrounding importantly contribute to glioblastoma progression (Charles, Holland 
et al. 2012, Quail and Joyce 2017). As we recently reviewed (Attachment 12), 
glioblastoma tissue contains various non-transformed elements such as 
microglia/macrophages, lymphocytes, neural precursor cells, neurons, 
pericytes/vascular smooth muscle cells, reactive astrocytes and endothelial cells. 
Together with extracellular matrix and the intratumoral fluid, these components 
constitute the tumor microenvironment. Intercellular interactions through cell-cell 
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contacts as well as secreted molecules and vesicles play an important role in promoting 
the malignant phenotype of cancer cell (Attachment 12, (Quail and Joyce 2017)).    
Attachment 5 provides a comprehensive overview of proteases that are deregulated in 
the glioblastoma microenvironment, and summarized their presumed role in disease 
pathogenesis. The deregulation of proteolytic balance in gliomas is a result of a 
complex set of processes including aberrant activation of several signaling pathways, 
physico-chemical changes in the tumor microenvironment and therapeutic interventions 
such as radiotherapy. Our bioinformatic analysis of the TCGA (The Cancer Genome 
Atlas) data revealed that several proteases are consistently up- or downregulated in 
glioblastomas and for a number of them (including DPP-IV and FAP) most marked 
upregulation was observed in the mesenchymal subtype of glioblastoma. Proteases 
importantly contribute to glioma progression and participate on various hallmarks of 
gliomas (see Attachment 5 for detailed information and references). For example, both 
extracellular (e.g. matrix metalloproteinases, urokinase type plasminogen activator and 
cathepsin B) and intracellular (e.g. calpain-2) proteases contribute to the increased 
invasiveness of glioma cells. This is not only due to their role in the breakdown and 
modification of extracellular matrix, but also due to their direct effect on cell adhesion 
molecules and cytoskeleton, and activation of motility promoting signal transduction 
cascades. Several proteases (e.g. presenilins, ADAMs, deubiquitinating enzymes, 
proteasome) play an important role in regulating the proliferation, self-renewal and 
apoptosis of glioma cells including stem-like cells. By activating protease activated 
receptor 2 (PAR2), proteases promote the formation of pseudopalisades, a typical 
morphological feature of glioblastomas (Dutzmann, Gessler et al. 2010). A number of 
proteases are also involved in the excessive neovascularization of glioblastomas acting 
as angiogenesis activators or inhibitors.  
 
Previous work in our laboratory showed that DPP-IV-like enzymatic activity is 
increased in glioblastomas, possibly due to the overexpression of DPP-IV and FAP in 
these tumors (Stremenova, Krepela et al. 2007). This was consistent with literature data 
and strongly suggested that both proteases may be involved in glioma pathogenesis (see 
Attachment 2 for a review). 
Mechanistic studies on the possible role of DPP-IV and its enzymatic activity in glioma 
cells (Attachment 6) were a continuation of my PhD work. We derived several primary 
cell cultures from glioblastomas using an explant technique in serum containing media. 
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Cell surface DPP-IV-like enzymatic activity, which is mostly derived from DPP-IV, 
negatively correlated with the colony forming capacity and proliferation of these 
cultures. We further confirmed that DPP-IV overexpression in three different permanent 
glioma cell lines led to a decreased cell growth in vitro due to a cell cycle block. 
Overexpression of transgenic DPP-IV also impaired glioma cell migration and 
adhesion. Using whole genome expression profiling we identified that a number of 
genes linked to cell proliferation, cell adhesion, migration and regulation of cell 
development and neuron differentiation were deregulated upon DPP-IV overexpression 
and may contribute to the observed phenotype changes. Forced expression of DPP-IV 
also reduced the growth of glioma cells in an orthotopic mouse xenotransplantation 
model. Interestingly, when an enzymatically inactive mutant DPP-IV carrying an active 
site Ser630Ala substitution was overexpressed in glioma cells, a similar phenotype was 
observed suggesting that the observed effects are in large part independent of the 
intrinsic enzymatic activity of the protease. These data are consistent with the tumor 
suppressive effects of DPP-IV reported in ovarian (Kajiyama, Kikkawa et al. 2002), 
prostate (Wesley, McGroarty et al. 2005) as well as non-small cell lung cancer cells 
(Wesley, Tiwari et al. 2004) and also in the tumor cells derived from neuroectoderm 
such as melanoma (Wesley, Albino et al. 1999) and neuroblastoma (Arscott, LaBauve et 
al. 2009). The growth inhibitory effects of DPP-IV in glioma cells might seemingly be 
in contradiction to the observation of higher DPP-IV expression and activity in glioma 
tissue homogenates (Stremenova, Krepela et al. 2007). The “net” pro- or anti-oncogenic 
effects of proteases nevertheless seems to represent an outcome of several factors 
including their differing functions in individual cell populations of both the tumor 
parenchyma and stroma, and varying (in)dependence of these functions on the intrinsic 
enzymatic activity. For example, forced expression of MT1-MMP was described to 
cause glioma cell death, although its presence in the tumor microenvironment promoted 
tumor expansion (Markovic, Vinnakota et al. 2009). Thus, DPP-IV may – independent 
of its enzymatic activity – negatively influence the proliferation of glioma cells, slowing 
their growth possibly as a part of an adaptive response to the limited nutrition supply or 
hypoxia (Dang, Chun et al. 2008), yet support angiogenesis or promote intratumoral 
deregulation of immune response through the proteolytic processing of neuropeptides 
and chemokines. By degrading the chemokines such as CXCL12 (SDF-1), DPP-IV 
might also impair the recruitment of tumor suppressive neural precursor cells 
(Chirasani, Sternjak et al. 2010, Charles, Holland et al. 2012) and as a result promote 
glioma progression.  
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Literature data indicated that DPP-IV is expressed in cancer stem-like cells in 
mesothelioma (Ghani, Yamazaki et al. 2011, Yamazaki, Naito et al. 2012) and is 
characteristic for highly metastatic cancer stem-like cells in colorectal carcinoma (Pang, 
Law et al. 2010). We have therefore analyzed whether DPP-IV is expressed in glioma 
stem-like cells (GSC). The derivation of primary cell cultures using serum containing 
media is known to lead to a preferential isolation of more differentiated cells. In 
addition, cell propagation in serum containing media induces substantial changes of the 
glioma cells so that the resulting cell lines only distantly represent the original tumor 
(Lee, Kotliarova et al. 2006). We isolated and characterized primary cell cultures from 
several GBMs which were propagated in defined serum-free medium favoring the 
expansion of GSCs. The majority of the GSC cultures exhibited expression of a stem 
cell marker CD133 as determined by flow cytometry and could undergo differentiation 
into GFAP and beta III tubulin expressing cells when transferred into serum containing 
media (Sana, Busek et al. 2018). We detected DPP-IV expression in part of the GSC 
cultures, the remaining cultures exhibited low or absent DPP-IV expression. There was 
a trend for decreased DPP-IV expression in cells differentiated using 10% serum (Busek 
et al. unpublished data), but this may be linked to the negative effect of serum on DPP-
IV expression in glioma cells (Balaziova, Busek et al. 2011). The GSC-cultures 
established in this study are being utilized in other projects of our laboratory, but our 
current results do not provide strong support for the possible role of DPP-IV in glioma 
stem-like cells.    
Attachment 7 contains our publication analyzing FAP expression in human gliomas 
and preclinical glioma models and its association with patient survival. As we have 
recently reviewed (Attachment 1), FAP may be expressed by transformed and stromal 
cells and has tumor specific and cell-type-dependent functions. FAP is predominantly 
expressed by tumor associated fibroblasts (CAF), but the presence of these cells in the 
unique tumor microenvironment of human gliomas is rather controversial. Several 
studies indicate that in some, but not all tumor types FAP overexpression is associated 
with a worse disease prognosis (reviewed in Attachment 1). Using mRNA 
quantification, previous reports including ours (Stremenova, Krepela et al. 2007, 
Mikheeva, Mikheev et al. 2010, Mentlein, Hattermann et al. 2011) suggested that FAP 
is upregulated in glioblastomas. We and others showed that FAP is expressed in glioma 
cells in vitro (Attachment 6, (Balaziova, Busek et al. 2011, Mentlein, Hattermann et al. 
2011)), nevertheless the quantity of FAP protein, its presence in various constituents of 
the glioma microenvironment and its relation to glioma patient survival were unknown. 
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In our patient cohort comprising 56 patients with newly diagnosed glioma, FAP 
expression was increased in glioblastomas compared to non-tumorous brain tissue 
(pharmacoresistant epilepsy, n = 15), in particular on the protein level. Our results 
revealed the presence of two to three molecular forms of FAP with an alkaline pI in 
GBM tissues, whereas glioma cell lines predominantly expressed forms with an acidic 
pI (Attachment 13). The amount of FAP protein as determined by ELISA and western 
blotting was highly heterogeneous in GBM, presumably reflecting the differences in 
FAP expression observed in individual molecular subtypes of GBM. Based on the 
TCGA data, FAP expression was highest in the mesenchymal subtype of glioblastoma 
with over 70 % of the mesenchymal tumors exhibiting at least a twofold upregulation 
compared to the controls. We further performed a gene set enrichment analysis of the 
transcripts that significantly positively correlated with FAP. Genes encoding various 
extracellular matrix proteins and factors involved in inflammation and wound healing 
were overrepresented and FAP expression also positively correlated with the transcripts 
for several proteases including DPP-IV.  
FAP expression was reported as a possible negative prognostic factor in several 
malignancies. We therefore analyzed the association between FAP expression and 
survival in our patient cohort and publicly available datasets. FAP expression was 
associated with patient survival in a dataset comprising both low-grade and high-grade 
tumors. Nevertheless as FAP expression is typical for glioblastomas as compared to 
low-grade tumors, the observed effect on survival is most likely due to the larger 
proportion of glioblastomas in the subgroups with higher FAP expression. In our patient 
cohort, the median survival was 48 weeks for glioblastoma (n = 42) and at the time of 
last follow-up, 60 % of grade III (n = 5) and 100 % of grade II (n = 7) patients were 
alive. Using Cox regression analysis we identified tumor grade, age at operation, and 
tumor volume as factors most strongly predicting patient survival in the whole 
experimental cohort. In glioblastoma, the combination of patient age and the presence of 
residual tumor had the highest predictive power. FAP expression as determined by qRT-
PCR, or western blotting neither alone nor in combination with the clinical variables 
was associated with patient survival in the whole patient cohort or in glioblastoma. 
Similarly, our analysis of two different publicly available microarray datasets revealed 




Using immunohistochemistry with a panel of monoclonal FAP antibodies, we observed 
three patterns of FAP expression in gliomas: fibrillary intraparenchymal positivity, 
predominantly perivascular positivity and the presence of both intraparenchymal and 
perivascular positivity. The fibrillary intraparenchymal FAP immunopositivity most 
likely corresponds to the presence of FAP in malignant cells – it colocalizes with the 
astrocytic marker GFAP and part of these intraparenchymal FAP
+
 also express SOX-2, 





cells in the majority of glioblastomas. These cells were absent in non-
malignant brain tissue, were predominantly localized around dysplastic blood vessels 
and lacked EGFR amplification, a molecular aberration typical for glioma cells. FAP 
expression in these cells colocalized with typical mesenchymal markers (smooth muscle 
actin (SMA) and TE-7) and regions with these cells contained substantial amounts of 
the mesenchymal extracellular matrix protein fibronectin. FAP expression was not 
detected in microglia or endothelial cells. We further investigated whether 
hematopoietic cells originating in the bone marrow may contribute to the FAP
+
 stromal 
subpopulation in human glioblastomas by determining the coexpression of CD45 in 
FAP
+





 cells could be detected in several glioblastomas. 
Collectively these data suggest that in addition to glioma cells, FAP is expressed by 
several other cellular types within the microenvironment of human glioblastomas.  
We further characterized FAP expression in glioma models that could be utilized in 
preclinical testing of FAP targeting therapies. For this purpose, a panel of permanent 
glioma cell lines, primary cell cultures derived from bioptic material and 
xenotransplants generated from these cell lines were utilized. Similarly to human 
bioptic material, FAP expression in glioma cells was variable in these preclinical glioma 
models. It was characteristically observed in serum derived primary cell cultures, U87 
cells and corresponding xenotransplants, whereas FAP expression in glioma stem-like 
cells (GSC) and U373 cells was low (Attachment 7 and unpublished data). The mouse 
xenotransplantation model also allowed assessment of FAP expression in the mouse 
stromal cells using a species specific real-time RT-PCR assay developed by us 
(Attachment 14). Stromal FAP mRNA expression was upregulated in the tumors 
compared to the contralateral hemisphere. These results were supported by 
immunohistochemical detection of FAP protein in mouse cells in close proximity of the 
tumors. Part of these cells coexpressed the CXCR4 chemokine receptor suggesting that 
these cells may be recruited to the tumors by chemotactic mediators released in the 
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tumor microenvironment. Collectively, FAP expression is upregulated in a subgroup of 
glioblastomas and FAP is expressed in both glioma cells and various types of stromal 
cells. FAP positive stromal cells in glioblastomas seem to have several characteristics of 
cancer associated fibroblasts (CAF) and mechanisms contributing to the tumor 
promoting effects of these cells seem to be conserved among various tumor types. In a 
collaborative project with the group of Prof. Smetana (Institute of Anatomy, First 
Faculty of Medicine Charles University), we have shown that cancer associated 
fibroblasts enhance the migration of glioma cells by soluble mediators and increase 
their growth by promoting cell proliferation (Attachment 15). An ongoing project in 
our laboratory evaluates whether FAP expressing stromal cells isolated from 
glioblastomas have similar effects.  
Existing treatment options in glioblastoma are limited and largely palliative. Selective 
expression of FAP in glioblastomas and putative tumor promoting effects of FAP 
expressing stromal cells may offer a possibility to develop new therapeutic approaches 
that would exploit FAP as a means to selectively deliver cytotoxic compounds into the 
tumors. This approach would allow simultaneous targeting of several components of the 
tumor microenvironment. In an effort to design and test new FAP targeting approaches 
we are collaborating with the group of Jan Konvalinka (Institute of Organic Chemistry 
and Biochemistry of The Czech Academy of Sciences). Inhibition of FAP enzymatic 
activity with a highly selective low molecular weight inhibitor prepared by Jansen et al. 
(Jansen, Heirbaut et al. 2014) did not affect glioma cell growth or invasiveness (Busek 
et al. unpublished data). Nevertheless, a specific interaction between this inhibitor and 
the highly conserved active site of the FAP protein can be used to create highly specific 
FAP targeting compounds. Attachment 8 contains our publication describing the 
synthesis and evaluation of an N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymer containing a FAP-specific inhibitor as the targeting ligand (an anti-FAP 
iBody). iBodies are novel tools for the targeting of proteins with a known ligand (Sacha, 
Knedlik et al. 2016). These biocompatible synthetic compounds offer several 
advantages compared to antibodies. iBodies are highly modular and versatile, and 
conjugates containing virtually any desired compound can be easily prepared. Synthetic 
HPMA conjugates have long been used as carriers for drug delivery to solid tumors, 
often making use of the enhanced permeability and retention (EPR) effect. In addition, 
the molecular weight of the HPMA backbone can be easily adjusted to specifically 
tailor the pharmacokinetic properties. An anti-FAP iBody exhibited high specificity for 
FAP, with minimal binding to the related proteases DPP-IV, DPP9 and prolyl 
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oligopeptidase. We have tested the utility of the anti-FAP iBody in a variety of 
biochemical assays that traditionally use antibodies such as pull-down, western blotting, 
ELISA, flow cytometry and immunohistochemistry. Interestingly, conjugation of the 
reversible inhibitor to a polymeric scaffold led to a very stable interaction between FAP 
and the anti-FAP iBody with a remarkably low dissociation rate. The iBody could be 
utilized to detect FAP expression in living cells using flow cytometry and in tissue 
sections using histochemistry. In living cells, binding of an anti-FAP iBody triggered 
FAP internalization, suggesting its suitability for targeted delivery of cytotoxic 
compounds. As expected, the anti-FAP iBody interacted with both human and mouse 
FAP due to the high conservation of the enzyme active site. Anti-FAP iBodies thus 
provide a tool that can be easily translated into preclinical mouse cancer models. In 
summary we designed, synthesized, and characterized a novel type of a highly selective 
FAP targeting agent, an iBody based on an HPMA copolymer decorated with a FAP 
inhibitor. The specificity, modularity, and versatility of the anti-FAP iBody make it 
suitable for a broad spectrum of biochemical and biomedical applications, including its 
use for in vivo imaging and selective drug delivery into the tumor microenvironment. 
 
Summary of the main results of our work in gliomas:  
 Several DPP-IV homologs are expressed in primary cell cultures derived from 
high-grade gliomas and the DPP-IV-like enzymatic activity is associated with 
their lower clonogenic capacity and slower proliferation. 
 Forced expression of DPP-IV in glioma cells decreases their proliferation by 
inducing a G2/M cell cycle block, and inhibits cell adhesion and migration. 
 Forced DPP-IV expression reduces glioma growth in an orthotopic xenograft 
model. 
 The observed anti-oncogenic effects of DPP-IV in glioma cells are in large part 
independent of its enzymatic activity. 
 A protocol for the derivation and propagation of glioblastoma stem-like cells 
(GSC) from bioptic material was successfully established in our laboratory. 
DPP-IV is variably expressed in GSC, FAP expression in these cultures is low. 
 FAP expression is increased in glioblastoma though with high inter-tumoral 
variability, possibly due to its differential expression in individual molecular 
subtypes of glioblastoma. 
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 FAP expression in glioblastoma is associated with the mesenchymal subtype of 
glioblastoma and correlates with the expression of genes encoding extracellular 
matrix proteins and several proteases. 
 FAP is expressed in malignant, presumably non-stem cells in glioblastoma and 
in several types of stromal cells including perivascularly localized mesenchymal 
cells and a small subset of CD45
+
 cells. 
 The overall quantity of FAP is not associated with patient survival in 
glioblastoma. 
 Prototype FAP targeting compounds based on a low molecular weight inhibitor 
(iBodies) were developed in collaboration with the group of Jan Konvalinka 
(Institute of Organic Chemistry and Biochemistry of The Czech Academy of 
Sciences).  
 Anti-FAP iBodies are highly specific towards FAP and can be used in a variety 
of biochemical and cell biology systems.  
 Using the iBody concept, we are currently developing and in preclinical models 




6. Concluding remarks and future perspectives  
Proteases constitute 2–3% of all known human genes and play an important role under 
physiological conditions and in the pathogenesis of the human malignancies. The view 
of these molecules in the field of cancer has shifted from their perception as mere 
“bulldozers” paving the road for cancer cell invasion to important regulators of various 
biological functions in the tumor microenvironment. In addition to the extracellular 
matrix remodeling, proteases cleave several regulatory biopeptides, cell surface 
receptors, ion channels and adhesion molecules, cytoskeletal proteins, components of 
the intracellular signaling cascades, and regulators of the cell cycle (reviewed in 
Attachment 5). In addition to their proteolytic activity, several proteases have non-
proteolytic functions which broaden their functional potential. 
In the presented thesis I summarized our studies which showed that DPP-IV and FAP 
may participate on the pathogenesis of a paraneoplatic form of diabetes (T3cDM) that 
accompanies pancreatic ductal adenocarcinoma (PDAC). From a clinical standpoint, 
differentiation of patients who develop diabetes as an early symptom of PDAC from the 
much more prevalent patients presenting with initial stage of a “typical“ type 2 DM 
holds a promise for a more timely diagnosis and thus an improved outcome of this 
dismal cancer. Unfortunately, none of the parameters evaluated in our studies had 
sufficient discriminatory power for distinguishing PDAC from type 2 DM. Recently 
reported approaches utilizing e.g. detection of circulating tumor DNA and a panel of 
protein biomarkers (Cohen, Javed et al. 2017) could be beneficial in this setting. We 
further demonstrated that DPP-IV and FAP are co-expressed in pancreatic alpha cells 
under physiological conditions. Mechanistic studies testing their possible function in 
Langerhans islets however need to be performed in order to understand their role in 
regulating insulin secretion. 
Our studies in glioblastoma revealed that, notwithstanding its upregulation in the tumor 
tissue, DPP-IV inhibits proliferation, adhesion and migration of glioma cells and 
reduces glioma growth in an orthotopic xenograft model independent of its enzymatic 
activity. This effect is consistent with reports in other tumor types demonstrating that 
DPP-IV is a tumor suppressor and illustrates that several proteases act as negative 
regulators of tumor progression (Lopez-Otin and Matrisian 2007). Our results also serve 
as an example of the fact that several proteases may execute their functions through 
non-proteolytic mechanisms (Del Rosso, Fibbi et al. 2002). 
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Upregulation of FAP in a subset of glioblastomas and its expression in transformed and 
stromal cells suggest that similarly to extracranial malignancies, this protease is 
overexpressed in primary brain tumors. Whether FAP contributes to glioma progression 
remains to be determined. Our study did not reveal association between overall levels of 
FAP in the glioblastoma tissue and patient survival. A more detailed analysis using 
bioptic material is currently ongoing together with experiments assessing the in vitro 
and in vivo effects of FAP overexpression or downmodulation in glioma cells and the 
role of FAP positive stromal cells derived from glioblastomas. Although there are 
several challenges (see Attachment 1 for a review), the possible use of FAP as a 
therapeutic target in glioblastoma and possibly other tumors that overexpress FAP is the 
focus of our ongoing projects. In cooperation with our colleagues at the Institute of 
Organic Chemistry and Biochemistry of The Czech Academy of Sciences (J. 
Konvalinka, P. Sacha, T. Knedlik) we are developing and testing FAP targeting 
compounds based on the iBody concept. FAP expression is variable even in tumors 
known to be generally FAP-positive (e.g. 36% of PDAC in our study (Attachment 4) 
had low FAP expression according to immunohistochemistry). Non-invasive analysis of 
FAP expression in the tumors considered for the application of FAP targeting 
treatments is important and we are therefore testing FAP PET probes that would be 
suitable for this purpose. 
In summary, in this thesis I have provided an overview of current studies on DPP-IV 
and FAP in cancer which together with our results suggest that these multifunctional 
molecules play a role in cancer pathogenesis. The available data also indicate that in 
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